{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:40:31Z","timestamp":1794541231674,"version":"4.9.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["NO.2023YFC3403700"],"award-info":[{"award-number":["NO.2023YFC3403700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Zevorcabtagene autoleucel (zevor-cel) is a fully human autologous CAR T-cell therapy targeting B-cell maturation antigen approved in China since 2024 for patients with relapsed\/refractory multiple myeloma (RRMM).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>LUMMICAR STUDY 1 is a phase 2, single-arm study conducted across 23 centers in China. RRMM patients aged\u2009\u2265\u200918 to \u2264\u200975 years with measurable disease who had received\u2009\u2265\u20093 prior lines of therapy, with adequate organ function and bone marrow reserve, with an Eastern Cooperative Oncology Group (ECOG) score of 0\u20131, were eligible. Patients previously treated with any CAR T-cell therapy, or any BCMA-directed therapy were ineligible. The primary endpoint was objective response rate (ORR) determined by an Independent Review Committee. The secondary endpoints included ORR determined by investigator, additional efficacy outcomes including complete response (CR)\/ stringent complete response (sCR) rate, duration of response (DOR), minimal residual disease negativity, safety outcomes including incidence and severity of adverse events, and pharmacokinetics of zevor-cel.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Overall, 125 patients underwent apheresis, 105 patients received lymphodepletion, 102 patients (median age of 59.5 [range: 38, 75] years; 53.9% male and 46.1% female) received zevor-cel. The ORR was 92.2% (95% CI 85.13\u201396.55) with 70 patients (68.6%) achieving sCR and 3 (2.9%) achieving CR. At a median follow-up of 20.3 (interquartile range [IQR] 12.5, 23.8) months, 45 (44.1%) progression-free survival (PFS) events and 20 (19.6%) overall survival (OS) events were observed, the DOR, PFS and OS data were not mature. Cytokine release syndrome was reported in 92 (90.2%) patients, with grade 3 or 4 events in 7 (6.9%) patients. Immune effector cell associated neurotoxicity syndrome was reported in 2 patients at grade 1; no zevor-cel-related grade\u2009\u2265\u20093 neurotoxicity occurred.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Zevor-cel induces deep and durable responses in heavily pre-treated RRMM patients with a manageable safety profile.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40164-025-00710-y","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T07:25:14Z","timestamp":1759217114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed\/refractory multiple myeloma"],"prefix":"10.1186","volume":"14","author":[{"given":"Wenming","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baijun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aibin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siguo","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songfu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunmin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishanthan","family":"Rajakumaraswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daijing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huamao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zonghai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"19","key":"710_CR1","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood.2020008735","volume":"139","author":"A Perrot","year":"2022","unstructured":"Perrot A. How I treat frontline transplantation-eligible multiple myeloma. Blood. 2022;139(19):2882\u20138.","journal-title":"Blood"},{"key":"710_CR2","doi-asserted-by":"crossref","first-page":"102537","DOI":"10.1016\/j.canep.2024.102537","volume":"89","author":"MA Casta\u00f1eda-Avila","year":"2024","unstructured":"Casta\u00f1eda-Avila MA, Su\u00e1rez-Ramos T, Torres-Cintr\u00f3n CR, Epstein MM, Gierbolini-Berm\u00fadez A, Tortolero-Luna G, et al. Multiple myeloma incidence, mortality, and survival differences at the intersection of sex, age, and race\/ethnicity: A comparison between Puerto Rico and the united States SEER population. Cancer Epidemiol. 2024;89:102537.","journal-title":"Cancer Epidemiol"},{"issue":"23","key":"710_CR3","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1097\/CM9.0000000000002600","volume":"136","author":"J Liu","year":"2023","unstructured":"Liu J, Liu W, Mi L, Cai C, Gong T, Ma J, et al. Burden of multiple myeloma in china: an analysis of the global burden of Disease, Injuries, and risk factors study 2019. Chin Med J. 2023;136(23):2834\u20138.","journal-title":"Chin Med J"},{"issue":"8","key":"710_CR4","doi-asserted-by":"crossref","first-page":"9604","DOI":"10.1002\/cam4.5737","volume":"12","author":"Y Yang","year":"2023","unstructured":"Yang Y, Li J, Wang W, Wang Y, Maihemaiti A, Ren L, et al. The evolving diagnosis and treatment paradigms of multiple myeloma in china: 15 years\u2019 experience of 1256 patients in a National medical center. Cancer Med. 2023;12(8):9604\u201314.","journal-title":"Cancer Med"},{"issue":"8","key":"710_CR5","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1038\/bcj.2014.55","volume":"4","author":"J Lu","year":"2014","unstructured":"Lu J, Lu J, Chen W, Huo Y, Huang X, Hou J, et al. Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. Blood Cancer J. 2014;4(8):e239\u2013e.","journal-title":"Blood Cancer J"},{"issue":"17","key":"710_CR6","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.3390\/cancers13174320","volume":"13","author":"L Gengenbach","year":"2021","unstructured":"Gengenbach L, Graziani G, Reinhardt H, R\u00f6sner A, Braun M, M\u00f6ller M-D, et al. Choosing the right therapy for patients with Relapsed\/Refractory multiple myeloma (RRMM) in consideration of Patient-, Disease- and Treatment-Related factors. Cancers (Basel). 2021;13(17):4320.","journal-title":"Cancers (Basel)"},{"issue":"17","key":"710_CR7","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.3390\/cancers14174082","volume":"14","author":"D Dima","year":"2022","unstructured":"Dima D, Jiang D, Singh DJ, Hasipek M, Shah HS, Ullah F, et al. Multiple myeloma therapy: emerging trends and challenges. Cancers (Basel). 2022;14(17):4082.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"710_CR8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","volume":"26","author":"SK Kumar","year":"2012","unstructured":"Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26(1):149\u201357.","journal-title":"Leukemia"},{"issue":"1","key":"710_CR9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","volume":"78","author":"IS Nijhof","year":"2018","unstructured":"Nijhof IS, Van De Donk NWCJ, Zweegman S, Lokhorst HM. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs. 2018;78(1):19\u201337.","journal-title":"Drugs"},{"issue":"3","key":"710_CR10","first-page":"275","volume":"73","author":"RH Parikh","year":"2023","unstructured":"Parikh RH, Lonial S. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice. CA Cancer J Clin. 2023;73(3):275\u201385.","journal-title":"CA Cancer J Clin"},{"key":"710_CR11","unstructured":"USFDA. FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma Accessed 08 Apr 2025."},{"issue":"9","key":"710_CR12","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1158\/1078-0432.CCR-21-3803","volume":"28","author":"P Sharma","year":"2022","unstructured":"Sharma P, Kanapuru B, George B, Lin X, Xu Z, Bryan WW, et al. FDA approval summary: Idecabtagene vicleucel for relapsed or refractory multiple myeloma. Clin Cancer Res. 2022;28(9):1759\u201364.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"710_CR13","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1002\/ctm2.346","volume":"11","author":"C Li","year":"2021","unstructured":"Li C, Cao W, Que Y, Wang Q, Xiao Y, Gu C, et al. A phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia. Clin Transl Med. 2021;11(3):e346.","journal-title":"Clin Transl Med"},{"issue":"6","key":"710_CR14","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene Autoleucel, an Anti-B-cell maturation antigen chimeric antigen receptor T-Cell Therapy, for Relapsed\/Refractory multiple myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023;41(6):1265\u201374.","journal-title":"J Clin Oncol"},{"issue":"8","key":"710_CR15","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LDJ, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"1","key":"710_CR16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2024","unstructured":"Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, et al. Safety and efficacy of standard of care ciltacabtagene autoleucel for Relapsed\/Refractory multiple myeloma. Blood. 2024;145(1):85\u201397.","journal-title":"Blood"},{"issue":"1","key":"710_CR17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","volume":"15","author":"W-H Zhao","year":"2022","unstructured":"Zhao W-H, Wang B-Y, Chen L-J, Fu W-J, Xu J, Liu J, et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J Hematol Oncol. 2022;15(1):86.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"710_CR18","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","volume":"29","author":"Y Lin","year":"2023","unstructured":"Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023;29(9):2286\u201394.","journal-title":"Nat Med"},{"issue":"8","key":"710_CR19","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3324\/haematol.2022.280629","volume":"107","author":"M Yang","year":"2022","unstructured":"Yang M, Zhang W, Yu K, Wang P, Jiang H, Chen L, et al. A novel BCMA CAR-T-cell therapy with optimized human ScFv for treatment of relapsed\/refractory multiple myeloma: results from phase I clinical trials. Haematologica. 2022;107(8):1960\u20135.","journal-title":"Haematologica"},{"issue":"1","key":"710_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/hgtb.2017.098","volume":"29","author":"C G\u00e1ndara","year":"2018","unstructured":"G\u00e1ndara C, Affleck V, Stoll EA. Manufacture of Third-Generation lentivirus for preclinical Use, with process development considerations for translation to good manufacturing practice. Hum Gene Ther Methods. 2018;29(1):1\u201315.","journal-title":"Hum Gene Ther Methods"},{"issue":"Supplement 1","key":"710_CR21","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1182\/blood-2018-99-113220","volume":"132","author":"S Jiang","year":"2018","unstructured":"Jiang S, Jin J, Hao S, Yang M, Chen L, Ruan H, et al. Low dose of human scFv-Derived BCMA-Targeted CAR-T cells achieved fast response and high complete remission in patients with Relapsed\/Refractory multiple myeloma. Blood. 2018;132(Supplement 1):960.","journal-title":"Blood"},{"issue":"Supplement 1","key":"710_CR22","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1182\/blood-2023-184373","volume":"142","author":"C Fu","year":"2023","unstructured":"Fu C, Chen W, Cai Z, Yan L, Wang H, Shang J, et al. Three-Year Follow-up on efficacy and safety results from phase 1 lummicar study 1 of Zevorcabtagene autoleucel in Chinese patients with relapsed or refractory multiple myeloma. Blood. 2023;142(Supplement 1):4845.","journal-title":"Blood"},{"key":"710_CR23","unstructured":"NMA Approval: Zevorcabtagene Autoleucel Injection. https:\/\/www.nmpa.gov.cn\/datasearch\/search-info.html?nmpa=aWQ9NmZiOWU3ODJlNWI2MmIxYWFlZGJkYmFmMmM5OTA4ZGUmaXRlbUlkPWZmODA4MDgxODNjYWQ3NTAwMTg0MDg4MWY4NDgxNzlm. Accessed 8 Apr 2025."},{"issue":"4","key":"710_CR24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"710_CR25","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jamaoncol.2024.4879","volume":"10","author":"C Li","year":"2024","unstructured":"Li C, Zhou K, Hu Y, Zou D, Chen L, Chen B, et al. Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: the FUMANBA-1 nonrandomized clinical trial. JAMA Oncol. 2024;10(12):1681\u20138.","journal-title":"JAMA Oncol"},{"issue":"Supplement 1","key":"710_CR26","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/blood-2024-204620","volume":"144","author":"W Chen","year":"2024","unstructured":"Chen W, Fu C, Fang B, Liang A, Xia Z, He Y, et al. Subgroup analyses of phase 2 study: evaluating the efficacy of fully human BCMA-Targeting CAR T cells (Zevorcabtagene Autoleucel) in patients with Relapsed\/Refractory multiple myeloma. Blood. 2024;144(Supplement 1):4762.","journal-title":"Blood"},{"key":"710_CR27","unstructured":"ABECMA\u00ae (idecabtagene vicleucel) PRESCRIBING INFORMATION.2024. https:\/\/www.fda.gov\/media\/147055\/download?attachment Accessed 08 Apr 2025."},{"key":"710_CR28","unstructured":"CARVYKTI\u00ae (ciltacabtagene autoleucel) PRESCRIBING INFORMATION. 2024. https:\/\/www.fda.gov\/media\/156560\/download Accessed 08 Apr 2025."},{"issue":"7","key":"710_CR29","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","volume":"390","author":"N Verdun","year":"2024","unstructured":"Verdun N, Marks P. Secondary cancers after chimeric antigen receptor T-Cell therapy. N Engl J Med. 2024;390(7):584\u20136.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"710_CR30","doi-asserted-by":"crossref","first-page":"7542","DOI":"10.1182\/blood-2022-159185","volume":"140","author":"J-Q Mi","year":"2022","unstructured":"Mi J-Q, Zhao W, Jing H, Fu W, Hu J, Chen L, et al. Phase 2, Open-Label study of ciltacabtagene Autoleucel, an Anti-BCMA CAR-T cell Therapy, in Chinese patients with Relapsed\/Refractory multiple myeloma (CARTIFAN-1): 26-Month median Follow-up. Blood. 2022;140(Supplement 1):7542\u20134.","journal-title":"Blood"},{"issue":"16suppl","key":"710_CR31","doi-asserted-by":"crossref","first-page":"8025","DOI":"10.1200\/JCO.2023.41.16_suppl.8025","volume":"41","author":"C Li","year":"2023","unstructured":"Li C, Wang D, Song Y, Huang H, Li J, Chen B, et al. CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed\/refractory multiple myeloma: updated results of phase 1b\/2 study (FUMANBA-1). J Clin Oncol. 2023;41(16suppl):8025.","journal-title":"J Clin Oncol"},{"key":"710_CR32","doi-asserted-by":"crossref","first-page":"1019548","DOI":"10.3389\/fimmu.2022.1019548","volume":"13","author":"H Li","year":"2022","unstructured":"Li H, Zhao L, Sun Z, Yao Y, Li L, Wang J, et al. Prolonged hematological toxicity in patients receiving BCMA\/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma. Front Immunol. 2022;13:1019548.","journal-title":"Front Immunol"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00710-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-025-00710-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00710-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T07:25:27Z","timestamp":1759217127000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-025-00710-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["710"],"URL":"https:\/\/doi.org\/10.1186\/s40164-025-00710-y","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Good Clinical Practice guidelines and the Declaration of Helsinki and was approved by the ethics committee of Affiliated Beijing Chaoyang Hospital of Capital Medical University (Approval No. 2019-\u836f-4). Patients (or parents\/guardians) provided written informed consent (or assent) prior to enrolment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"119"}}